Pacira BioSciences (PCRX) Total Current Liabilities (2010 - 2026)

Pacira BioSciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 65.44% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $108.8 million (down 65.44% YoY), while the FY2025 annual figure was $120.6 million, down 61.09% from the prior year.
• Total Current Liabilities was $108.8 million for Q1 2026 at Pacira BioSciences, down from $120.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $314.7 million in Q1 2025 to a low of $92.7 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $169.6 million across 5 years, with a median of $120.6 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 71.64% in 2022, then surged 237.86% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $147.8 million in 2022, then sank by 34.1% to $97.4 million in 2023, then surged by 218.25% to $309.9 million in 2024, then tumbled by 61.09% to $120.6 million in 2025, then decreased by 9.79% to $108.8 million in 2026.
• The last three Total Current Liabilities figures came in at $108.8 million (Q1 2026), $120.6 million (Q4 2025), and $107.1 million (Q3 2025), per Business Quant data.